Serotonin (5-hydroxytryptamine, 5-HT) was first identified in serum in 1949 by M. Rapport.' At k that time, the importance of 5-HT was quite modest: The serum vasoconstrictor that appeared when blood was allowed to clot was an important source of artifactual vasoconstriction in investigations aimed at discovering substances possibly causing hypertension. Since then, however, a great interest has been endowed to 5 -HT research, as indicated by the remarkable number of full publications in this area of research.
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In mammals, about 90% of 5-HT present in the body is stored in the gastrointestinal tract, mainly in enterochromaffin cells. Of the remaining 5-HT, most is present in cells of the central nervous system and circulating platelets. Part of the 5-HT that is released by enterochromaffin cells overflows to the capillary blood and reaches the liver through the portal circulation. In the liver, most of it is degraded enzymatically. Of the remaining fraction, little escapes the uptake by the pulmonary endothelium that inactivates it by means of monoamine oxidase and catechol-O-methyltransferase. The final fraction of 5-HT present in the plasma is taken up avidly by platelets, which store it in their dense granules. As a consequence, as long as platelets do not aggregate, peripheral arterial blood contains little or no free 5 -HT. However, whenever platelet aggregation is initiated and dense granules release their contents, 5-HT is liberated in the blood and can exert its pathophysiological effects through activation of specific membrane receptors.
5-HT Receptors
The first major attempt to classify serotonergic receptors was by Gaddum and Picarelli2 in 1957, who described "D" and "M" receptors in the guinea pig ileum according to whether the response to 5 5-HT has complex and sometimes opposite effects on blood vessels, its net results being dependent on the species, the route of administration, the experimental conditions under which the amine is released or administered, and the presence of a functional endothelium. A particular difficulty in unraveling the vascular effects of serotonin has been the lack of selective antagonists against its different receptors. Recently, however, a number of 5-HT receptor antagonists, such as ketanserin, have become available for experimental and clinical studies. These new drugs have proved to be extremely useful in increasing our understanding of the pathophysiological role of 5-HT in a variety of cardiovascular disorders. A few years ago, the consensus in the field was that the arterial constriction induced by 5-HT was almost invariably mediated by activation of 5-HT2 receptors,6 with the possible exception of cerebral arterial vessels.6 Later studies, however, described that under some circumstances, 5-HT-induced coronary constriction can be partly mediated by activation of 5-HT1 receptor subtypes.
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In Vivo Studies of the Coronary Circulation
Because of the existence of a number of different cellular systems that potentially may be affected by 5 -HT, the effects of 5-HT are much more complex in vivo. First, once 5-HT is released by activating platelets, the first targets probably are the platelets themselves. Indeed, the monoamine activates serotonergic receptors of the 5 -HT2 subtype on the platelet membrane. This accelerates the turnover of phosphoinositides, resulting in an activation of the platelets and release of other vasoactive substances, such as thromboxane A2, which may result in coronary vasoconstriction as well. The importance of this platelet-mediated coronary vasoconstriction is outlined by studies conducted in dogs with experimental coronary stenosis and endothelial injury in which platelet activation leads to a marked coronary vasoconstriction at the site of platelet-vessel wall interaction.12 It is worth emphasizing that this vasoconstriction can be prevented or significantly reduced by administration of selective 5-HT2 receptor antagonists, suggesting a prominent role of these 5-HT receptor subtypes in causing this platelet-related coronary vasoconstriction. 12 At the arteriolar level and in a number of large conduit vessels, 5 -HT causes the relaxation of vascular smooth muscle and thus dilation. There is general agreement that this 5-HT-induced vasodilation is mediated through activation of 5 -HT, receptors located on endothelial cells with the consequent release of endothelium-derived relaxing factor (in the form of nitric oxide or a nitrosoderivative yielding nitric oxide). Thus, it can be anticipated that the effects of 5-HT in the intact coronary circulation will be complex. Indeed, Brum et al13 and Lamping et al14 reported that in anesthetized dogs, 5-HT caused dose-dependent constriction of coronary arteries with injured endothelium. In contrast, Chu and Cobb15 showed that in conscious dogs without endothelial damage, 5-HT caused a dose-related biphasic response characterized by an initial increase in coronary artery diameter followed by a delayed vasoconstriction. Hence, the in vivo vascular responses to 5--HT will depend, at least in part, on the integrity of the endothelial cell lining. If the latter is intact, it will form a diffusion barrier preventing the monoamine from permeating into the media; in addition, the endothelial cells take up the monoamine and degrade it enzymatically or store it. The 5-HT reaching 5 -HT1 serotonergic receptors on the endothelial cells will trigger the release of endothelium-derived relaxing factor. This not only will cause relaxation of the underlying vascular smooth muscle but also will help to prevent platelet adhesion and curtail platelet aggregation. '6 Studies conducted in humans also provide evidence that 5-HT has complex effects on the coronary circulation. In patients with normal coronary arteries, 5-HT causes a dose-dependent increase in coronary blood flow as well as an increase in the diameter of the coronary artery where the amine was infused. These vasodilating effects were mediated through activation of non-5-HT2 receptors, since they were not blunted but instead potentiated after administration of ketanserin. '7 In contrast, in patients with coronary atherosclerotic lesions, intracoronary infusions of 5-HT caused a dosedependent vasoconstriction evidenced by a decrease in both coronary artery diameter and flow. Interestingly, the vasoconstricting effects of 5 -HT in patients with coronary atherosclerosis were completely blocked after administration of ketanserin, thus suggesting a role of activation of 5-HT2 subtype receptors. ' 
